Preview

Антибиотики и Химиотерапия

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Антиинфекционное, антитоксическое и антипаразитарное действие экзогенной ДНК

Полный текст:

Об авторах

Н. Н. Беседнова
Научно-исследовательский институт эпидемиологии и микробиологии Сибирского отделения РАМН
Россия


Т. С. Запорожец
Научно-исследовательский институт эпидемиологии и микробиологии Сибирского отделения РАМН
Россия


Список литературы

1. Хаитов Р. М., Пинегин Б. В. Иммуномодуляторы: механизм действия и клиническое применение. Иммунология 2003; 24: 4: 196-203.

2. Yamamoto S., Yamamoto T., Shimada S. et al. DNA from bacteria? But not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992; 36: 983-997.

3. Krieg A. M. CpG motifs: the active ingredient in bacterial extracts? Natur Med 2003; 9: 7: 831-835.

4. Krieg A. M. Antiinfective spplications of Toll-like receptor 9 agonist. Amer Thoracis Society 2007; 4: 289-294.

5. Bird A. P. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209.

6. Dodge J. E., Ramsahoyeb B. H., Woa Z. G. et al. De novo methylation of MMLV provirus in embryonic stem cell: CpG versus non-CpG methylation. Gene 2002; 289: 1-2: 41-48.

7. Mitra S. K., Gupta M., Sarma D. N. Immunomodulatory effect of IM-133. Phytother Res 1999; 4: 341-343.

8. Cornelie S., Poulain-Godefroy O., Lund C. et al. Methylated CpG-containing plasmid activates the immune system. Scand J Immunol 2004; 59: 2: 143-151.

9. Kensuke M. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Sem Immunol 2007; 19: 3-10.

10. Bandholtz L. C. DNA Vaccines and bacterial DNA in Immunity. Doctoral Thesis 2002; Stockholm. 44.

11. Vollmer J., Krieg A. M. Immunotherapeutic applications of CpG-oligodeoxynucleotides TLR9 agonist. Adv Drug Deliv Rev 2009; 61: 3: 195-204.

12. Dorn A., Kippenberger S. Clinical application of CpG, non-CpG and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther 2006; 10: 10-20.

13. Jurk M., Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonist for immune modulation. Bio Drugs 2007; 21: 387-401.

14. Афанасьев С. С., Алешкин В. A., Байракова А. Л. и др. Молекулярные механизмы индукции врождённого иммунитета. Вестник РАМН 2009; 4: 42-49.

15. Mutwiri G., Gerdts V., Lopez M., Babiuk L. A. Innate immunity and new adjuvants. Rev Sci Tech Int Epiz 2007; 26: 1: 147-156.

16. Gupta K, Cooper C.A. Review ofthe Role ofCpG ODN as Toll-like receptor-agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs in Rand D 2008; 9: 3: 137-145.

17. Gursel M., Verthelyi D., Gursel I. et al. Differential and competitive activation of human immune cells by distinct classes of CpG ODN. J Leukoc Biol 2002; 71: 813-820.

18. Klinman D. M. Immunotherapeutic uses of CpG ODN. Nat Rev Immunol 2004; 4: 152-166.

19. Krieg A. M., Yi A. K., Matson S. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.

20. Neujahr D. C., Pisetsky D. S. DNA as an adjuvant. Vaccine adjuvantes: Preparation Methods and Research Protocols. 2000; 42: 299-313.

21. Walker P. S., Scharton-Kersten T., Krieg A. M. et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leischmaniasis via IL-12 and IFNγ - dependent mechanisms. Med Scienc 1999; 96: 12: 6970-6975.

22. Беседнова H. H., Касьяненко Ю. И., Эпштейн Л. М., Гажа А. К. Иммунотропные свойства дезоксирибонуклеиновой кислоты. Антибиотики и химиотер 1999; 10: 13-15.

23. Gomis S., Babiuk L., Godson D. L. et al. Protection of chickens against coli infection by DNA containing CpG motifs. Infect Immun 2003; 71: 2: 857-863.

24. Zhu Y.-M., Miao J.-F., Fan H.-J. et al. Protective effect of CpG-DNA against mastitis induced by Staphylococcus aureus infection in a rat model. Intern Immunopharmacol 2007; 7: 4: 435-443.

25. Bhan U., Trjillo G., Lyn-Kew K. et al. Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. Infect Immunol 2008; 76: 7: 2895-2904.

26. Elkins K. L., Colombini S. M., Krieg A. M., De Pascalis R. NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. Microb Infect 2009; 11: 1: 49-56.

27. Klinman D. M., Xie H., Ivins B. E. CpG-ODN improve the protective immune response induced by the licensed anthrax vaccine. Ann NY Acad Sci 2006; 1082: 137-150.

28. Weighardt H., Feterowski C., Veit M. et al. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides in related to an enhanced innate effector cell response. J Immunology 2000; 165: 4337-4543.

29. Одинцов Ю. H., Перельмутер В. М. Последствия интернализации и фагоцитоза листерий при инфекционном процессе. Бюлл Сибирской мед 2003; 4: 120-126.

30. Krieg A. M., Love-Homan L., Yi A. -K., Harty J. T. CpG-DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunology 1998; 161: 2428-2434.

31. Ito S., Ishii K. J., Gursel M. et al. CpG-ODN enhance neonatal resistance to Listeria infection. Ibid 2005; 174: 777-782.

32. Ishii K. J., Ito Sh., Tamura T. et al. CpG-activated Thy1. 2+-dendritic cells protect against lethal Listeria monocytogenes infection. Eur J Immunol 2005; 35: 8: 2397-2405.

33. Ray N. B., Krieg A. M. Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. Infection Immunity 2003; 78: 8: 4398-4404.

34. Oxenius A., Martinic M. A., Hengartner H., Klenerman P. CpG-containing O DN are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccine. J Virology 1999; 73: 5: 4120-4126.

35. Федянина Л. H. Иммуномодулирующая активность низкомолекулярной дезоксирибонуклеиновой кислоты (ДНК) из молок лососевых рыб (фундаментальные и прикладные аспекты). Автореф. дисс.. докт. мед. наук. Владивосток. 2007; 46.

36. Cong Y., Jupelli M., Guentzel N. et al. Intranasal immunization with chlamidial protease-like activity factor and CpG-ODN enhances protective immunity against genital Chlamidia muridarum infection. Vaccine 2007; 25: 5: 3773-3780.

37. Нестеров И. М., Тотолян А. А. Иммунокорригирующая терапия инфекционно-воспалительных заболеваний женской половой сферы. СПб. 2007; 56.

38. Juffermans M. P., Leemans J. C., Florquin S. et al. CpG-ODN enhance host defense during murine tuberculosis. Infect Immun 2002; 70: 1: 147-152.

39. Wang J. P., Hayashi T., Datta S. K. et al. CpG-ODN partially inhibit growth of Mycobacterium tuberculosis but not Salmonella or Listeria, in human monocyte-derived macrophages. FEMS Immunol Med Microbiol 2006; 45: 2: 303-310.

40. Yamamoto S., Yamamoto T., Nojima Y. et al. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis 2002; 55: 37-44.

41. Rhee E. G., Mendez S., Shah J. A. et al. Vaccination with heat-killed leischmania antigen or recombinant leischmanial protein and CpG-ODN induced long-term memory CD4+ and CD8+ T cell responses and protection against Leischmania major infection. J Exp Med 2002; 195: 12: 1565-1573.

42. Verthelyi D., Gursel M., Kenney R. T. et al. CpG-ODN protect normal and SIV infected macaques on Leischmania infection. Infect Immunol 2005; 73: 8: 4948-4954.

43. Flinn B., Wang W., Sacks D. L. et al. Prevention and treatment cutaneous leischmaniasis in primates by using synthetic type D/A ODN expressing CpG motifs. Infect Immunity 2005; 73: 8: 4948-4954.

44. Tafagodi M., Tabassi A. S., Amiri N. PLGA Nanospheres loaded with autoclaved Leischmania major (ALM) and CpG-ODN: preparation and in vitro characterization. Iranian J Basic Med Sci 2008; 11: 2: 112-119.

45. Ivory P. A., Chadee K. Intranasal immunization with gal-inhibitable lectin plus an adjuvant of CpG-ODN protects against Entamoeba histolytica challenge. Infection and Immunity 2007; 75: 10: 4817-4922.

46. Saavedra R., Leyva R., Tenorio E. P. et al. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii. Parasite Immunology 2004; 26: 2: 367-373.

47. Barrier M., Lacroix-Lamande S., Mancassola R. et al. Oral and intraperitoneal administration of phosphorotioate ODN leads to control of Cryptosporidium parvum infection in neonatal mice. J Infect Dis 2006; 193: 10: 1400-1407.

48. Dalloul R. A., Lillehoj H. S., Okamura M et al. In vivo effect of CpG ODN on Eimeria infection in chickens. Avian Dis 2004; 48: 783-790.

49. Ходырев А. П. Влияние нуклеиновых кислот на исход острой стрептококковой инфекции. Журн эпидемиол микробиол имму-нобиол 1974; 10: 70-74.

50. Павлинич С. Н. Экспериментальное обоснование применения низкомолекулярной ДНК из молок лососевых рыб и напитков на натуральной основе с низкомолекулярной ДНК при псевдотуберкулезе: автореф. дисс.. канд. мед. наук. Владивосток: 2006; 24.

51. Luganini A., Caposio P., Landolfo S., Grubaudo G. Phosphorotioatemodified ODNs inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob Agents Chemother 2008; 53: 3: 1111-1120.

52. Hook E. W., Cannon R. O., Nahmias F. F. et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992; 65: 251.

53. Harandi A. M. The potential immunostimulatory CpG-DNA for inducing immunity against genital herpes: opportunities and challenges. J Clin Virol 2004; 23: 207-210.

54. Wong J. P., Nagata L. P., Christopher M. E. et al. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 2005; 23: 2266-2268.

55. Isogawa M., Robek M. D., Furuichi Y., Chisari F. V. Toll-like receptor signalling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-7272.

56. Jiao X., Wang Y.-H., Qiu O. et al. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J General Virolog 2004; 85: 1545-1553.

57. Vincent I. E., Lucifora J., Durantel D. et al. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther 2009; 14: 1: 131-135.

58. Christopher M. E., Wong J. P. Broad-spectrum drugs against viral agents. Int J Mol Sci 2008; 9: 1561-1594.

59. Носик Д. H., Каплина Э. Н. Применение препарата ферровир в лечении инфекционной патологии. М.: 2007; 79.

60. Wagner H., Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002; 360: 229-230.

61. Аршинцева E. Г., Игнатьев В. H., Щукин С. А. Деринат в комплексной терапии геморрагической лихорадки с почечным синдромом // Новые технол диагн леч инфекц бол. VII Росс. съезд инфекц: Тез докл. 2006. Нижний Новгород. 2006; 225.


Для цитирования:


Беседнова Н.Н., Запорожец Т.С. Антиинфекционное, антитоксическое и антипаразитарное действие экзогенной ДНК. Антибиотики и Химиотерапия. 2010;55(7-8):46.

For citation:


Besednova N.N., Zaporozhets T.S. Antiinfective, Antitoxic and Antiparasitic Effects of Exogenic DNA. Antibiotics and Chemotherapy. 2010;55(7-8):46. (In Russ.)

Просмотров: 22


ISSN 0235-2990 (Print)